The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.